@article{Haugen_van der Hagen_2009, title={Bruk av amniocenteser og chorionbiopsier i Norge}, volume={7}, url={https://www.ntnu.no/ojs/index.php/norepid/article/view/351}, DOI={10.5324/nje.v7i1.351}, abstractNote={<strong><span style="font-family: TimesNewRomanPS-BoldMT;"><span style="font-family: TimesNewRomanPS-BoldMT;"><p align="left"> </p></span></span><span style="font-size: x-small; font-family: TimesNewRomanPS-BoldMT;"><span style="font-size: x-small; font-family: TimesNewRomanPS-BoldMT;">SAMMENDRAG</span></span></strong><span style="font-size: x-small; font-family: TimesNewRomanPSMT;"><span style="font-size: x-small; font-family: TimesNewRomanPSMT;"><p align="left">Invasiv prenatal diagnostikk i form av amniocentese (fostervannsprøve) og chorionbiopsi (morkakeprøve)</p><p align="left">utføres i ca. 2% av alle svangerskap i Norge per år. Dette er betydelig færre undersøkelser enn</p><p align="left">hva som utføres i de andre nordiske land. De fleste får utført amniocentese pga. høy maternell alder</p><span style="font-size: x-small; font-family: TimesNewRomanPSMT;"><span style="font-size: x-small; font-family: TimesNewRomanPSMT;"><p align="left">(aldersindikasjon) som her i landet er</p></span></span></span><span style="font-size: x-small; font-family: TimesNewRomanPSMT;"><p align="left"> </p></span></span><p align="left"><span style="font-size: x-small; font-family: TimesNewRomanPSMT;"><span style="font-size: x-small; font-family: TimesNewRomanPSMT;">≥ </span></span><span style="font-size: x-small; font-family: TimesNewRomanPSMT;"><span style="font-size: x-small; font-family: TimesNewRomanPSMT;">38 år ved fødselstermin. Chorionbiopsi er forbeholdt kvinner<p align="left">med kjente arvelige lidelser i familien, dvs. kvinner med høy risiko for å få et affisert foster. De undersøkelser</p><p align="left">som foreligger over svangerskapsutfall samt forekomst av komplikasjoner etter amniocentese</p><span style="font-size: x-small; font-family: TimesNewRomanPSMT;"><span style="font-size: x-small; font-family: TimesNewRomanPSMT;"><p align="left">og chorionbiopsi er hovedsakelig utført i andre land på kvinner med generelt lavere risiko (</p></span></span></span><span style="font-size: x-small; font-family: TimesNewRomanPSMT;"><p align="left"> </p></span></span></p><p align="left"><span style="font-size: x-small; font-family: TimesNewRomanPSMT;"><span style="font-size: x-small; font-family: TimesNewRomanPSMT;">≥ </span></span><span style="font-size: x-small; font-family: TimesNewRomanPSMT;"><span style="font-size: x-small; font-family: TimesNewRomanPSMT;">35 år) enn<p align="left">for dem som får utført invasiv prenatal diagnostikk i Norge. Pga. vår restriktive praksis kan ikke disse</p><p align="left">resultatene uten videre overføres til Norge. Vi mangler eksakte data over svangerskapsutfall og evt.</p><p align="left">komplikasjoner etter disse undersøkelsene i en norsk populasjon.</p><span style="font-size: x-small; font-family: TimesNewRomanPSMT;"><span style="font-size: x-small; font-family: TimesNewRomanPSMT;"><p align="left">Haugen G, van der Hagen CB.</p></span></span></span><span style="font-size: x-small; font-family: TimesNewRomanPSMT;"><p align="left"> </p></span></span></p><p align="left"><strong><span style="font-size: x-small; font-family: TimesNewRomanPS-BoldMT;"><span style="font-size: x-small; font-family: TimesNewRomanPS-BoldMT;">The use of amniocentesis and chorionic villus sampling in Norway.</span></span></strong><em><span style="font-size: x-small; font-family: TimesNewRomanPS-ItalicMT;"><span style="font-size: x-small; font-family: TimesNewRomanPS-ItalicMT;"><em><span style="font-size: x-small; font-family: TimesNewRomanPS-ItalicMT;"><span style="font-size: x-small; font-family: TimesNewRomanPS-ItalicMT;"><p align="left">Nor J Epidemiol</p></span></span></em></span><em><span style="font-size: x-small; font-family: TimesNewRomanPS-ItalicMT;"><p align="left"> </p></span></em></span><strong><span style="font-size: x-small; font-family: TimesNewRomanPS-BoldMT;"><span style="font-size: x-small; font-family: TimesNewRomanPS-BoldMT;">ENGLISH SUMMARY</span></span></strong><span style="font-size: x-small; font-family: TimesNewRomanPSMT;"><span style="font-size: x-small; font-family: TimesNewRomanPSMT;"><p align="left">Amniocentesis or chorionic villus sampling are performed in about 2% of all pregnancies in Norway</p><p align="left">which is far less than in the other Nordic countries. Most of the amniocenteses are performed due to</p><span style="font-size: x-small; font-family: TimesNewRomanPSMT;"><span style="font-size: x-small; font-family: TimesNewRomanPSMT;"><p align="left">advanced maternal age. In Norway this is defined as maternal age</p></span></span></span><span style="font-size: x-small; font-family: TimesNewRomanPSMT;"><p align="left"> </p></span></span><p align="left"><span style="font-size: x-small; font-family: TimesNewRomanPSMT;"><span style="font-size: x-small; font-family: TimesNewRomanPSMT;">≥ </span></span><span style="font-size: x-small; font-family: TimesNewRomanPSMT;"><span style="font-size: x-small; font-family: TimesNewRomanPSMT;">38 years at term. Couples with<p align="left">known chromosomal aberrations or genetic diseases in their families, i.e. women at a high risk of having</p><p align="left">an affected fetus, are offered chorionic villus sampling. Earlier studies on complications and pregnancy</p><p align="left">outcome following amniocentesis or chorionic villus sampling have been performed in other countries</p><span style="font-size: x-small; font-family: TimesNewRomanPSMT;"><span style="font-size: x-small; font-family: TimesNewRomanPSMT;"><p align="left">mainly on women at a lower risk (</p></span></span></span><span style="font-size: x-small; font-family: TimesNewRomanPSMT;"><p align="left"> </p></span></span></p><p align="left"><span style="font-size: x-small; font-family: TimesNewRomanPSMT;"><span style="font-size: x-small; font-family: TimesNewRomanPSMT;">≥ </span></span><span style="font-size: x-small; font-family: TimesNewRomanPSMT;"><span style="font-size: x-small; font-family: TimesNewRomanPSMT;">35 years) than for the women having such tests in Norway. We do<p align="left">not have data on pregnancy outcome and possible complications following amniocentesis and chorionic</p><p>villus sampling in a Norwegian population.</p></span></span></p></em><span style="font-size: x-small; font-family: TimesNewRomanPSMT;"><span style="font-size: x-small; font-family: TimesNewRomanPSMT;">1997; </span></span><strong><span style="font-size: x-small; font-family: TimesNewRomanPS-BoldMT;"><span style="font-size: x-small; font-family: TimesNewRomanPS-BoldMT;">7 </span></span></strong><span style="font-size: x-small; font-family: TimesNewRomanPSMT;"><span style="font-size: x-small; font-family: TimesNewRomanPSMT;">(1): 29-32.</span></span></p>}, number={1}, journal={Norsk Epidemiologi}, author={Haugen, Guttorm and van der Hagen, Carl Birger}, year={2009}, month={Oct.} }